In this pharmacogenetic study, clinical outcomes such as severe thrombocytopenia hematological toxicity and overall survival of NSCLC patients with platinum-based chemotherapy were associated with linked non-coding variants of SLC31A1 gene that codes the transporter for platinum agent intake. This evidence concerns the gene SLC31A1 and Thrombocytopenia.